mantle cell lymphoma

News

FDA hands BeOne, Taiho approvals for blood cancers

BeOne gets the nod for BCL2 inhibitor Beqalzi in mantle cell lymphoma, while Taiho's Inqovi has acute myeloid leukaemia added to its label.

News

FDA starts priority review of BeOne's Venclexta rival

BeOne nears a possible FDA okay for sonrotoclax in mantle cell lymphoma, hoping to be the second BCL-2 inhibitor in the US after AbbVie's Venclexta.

News

NICE backs new drugs for Crohn's disease, lymphoma

Eli Lilly's Omvoh has been recommended for use in Crohn's disease by NICE, while BeOne's Brukinsa gets the go-ahead for mantle cell lymphoma.

News

Microscope view of nodular mantle cell lymphoma

AZ's Calquence gets first-line OK in mantle cell lymphoma

AstraZeneca's BTK inhibitor Calquence is the first drug in the class to be approved in the US for first-line treatment of mantle cell lymphoma.

News

AZ’s Calquence extends disease-free survival in MCL

AstraZeneca’s Calquence has been shown to improve progression-free survival in previously untreated mantle cell lymphoma (MCL), with an unprecedented trend towards improved overall survival

News

Lilly breaks new ground for BTK class with Jaypirca approval

Eli Lilly has picked up an FDA approval for its non-covalent BTK inhibitor Jaypirca in relapsed mantle cell lymphoma (MCL) patients who relapse after treatment with current drugs in the cla

FDA hands BeOne, Taiho approvals for blood cancers

FDA starts priority review of BeOne's Venclexta rival

NICE backs new drugs for Crohn's disease, lymphoma

AZ's Calquence gets first-line OK in mantle cell lymphoma

AZ’s Calquence extends disease-free survival in MCL

Lilly breaks new ground for BTK class with Jaypirca approval

OpenBind unveils its first AI model for drug discovery

Discover a new era of healthcare panel engagement: Grounded ...

mantle cell lymphoma

Editor's Picks